A longitudinal, single site study to evaluate the long term efficacy natalizumab therapy in patients with multiple sclerosis

Trial Profile

A longitudinal, single site study to evaluate the long term efficacy natalizumab therapy in patients with multiple sclerosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biogen
  • Most Recent Events

    • 28 Apr 2017 Results (n= 135) of preliminary analysis comparing baseline characteristics of patients treated with natalizumab versus healthy control, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 24 Feb 2016 New trial record
    • 10 Oct 2015 Interim analysis (n=35) presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top